Recursion Pharmaceuticals (RXRX) Shares Outstanding (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Shares Outstanding data on file, last reported at $530.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 30.56% year-over-year to $530.6 million; the trailing twelve-month figure through Mar 2026 stood at $530.6 million (up 30.56% YoY), and the FY2025 full-year result was $528.2 million, up 33.11% from the prior year.
• Shares Outstanding for Q1 2026 stood at $530.6 million, roughly flat from $528.2 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $530.6 million in Q1 2026 and bottomed at $171.1 million in Q1 2022.
• The 5-year median for Shares Outstanding is $237.5 million (2024), against an average of $302.9 million.
• Peak annual rise in Shares Outstanding reached 611.74% in 2022, while the deepest fall reached 2.61% in 2022.
• A 5-year view of Shares Outstanding shows it stood at $191.0 million in 2022, then gained by 22.64% to $234.3 million in 2023, then surged by 69.38% to $396.8 million in 2024, then surged by 33.11% to $528.2 million in 2025, then increased by 0.46% to $530.6 million in 2026.
• The last three Shares Outstanding figures came in at $530.6 million (Q1 2026), $528.2 million (Q4 2025), and $491.8 million (Q3 2025), per Business Quant data.

Peer Comparison